Tirzepa

Tirzepatide is a dual GIP and GLP-1 receptor agonist peptide. Each vial contains 20mg of lyophilized powder for reconstitution.

• Dual GIP/GLP-1 receptor agonist
• 20mg per vial
• Lyophilized powder — requires reconstitution with bacteriostatic water
• Store in a cool, dry place away from light

   

  Its primary effects include:

  • Reducing appetite and food intake, helping people feel fuller for longer.

  • Improving blood sugar control by enhancing insulin secretion when glucose levels are elevated.

  • Slowing stomach emptying, which can contribute to increased satiety.

  • Supporting significant weight loss in many patients.

  Tirzepatide is approved in several countries for the treatment of Type 2 Diabetes and obesity under brand names such as Mounjaro and Zepbound.

  Compared with traditional GLP-1 medications, tirzepatide's additional action on the GIP receptor may contribute to greater weight-loss and metabolic benefits in some individuals.